Literature DB >> 10997968

Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes.

K Shimazaki1, K Ohshima, J Suzumiya, C Kawasaki, M Kikuchi.   

Abstract

The myelodysplastic syndromes (MDS) are a group of disorders characterized by peripheral pancytopenia despite normo- or hypercellular bone marrow. This is thought to be as a result of the apoptosis of haematopoietic bone marrow cells resulting in ineffective haematopoiesis. To clarify the relationship between prognosis and apoptosis and/or cell proliferation in the bone marrow, we studied 51 cases with MDS. Bone marrow biopsies were stained immunohistochemically for MIB-1 (marker for proliferating cells) and CD34 (marker for stem cells). Apoptosis was visualized by detection of DNA fragmentation using TdT incorporation of nucleotides on 3' ends of DNA (TUNEL technique) and expressed as the apoptotic rate. MDS patients included 32 with refractory anaemia (RA), one RA with ringed sideroblasts (RARS) patient, seven RA with excess of blasts (RAEB) patients, eight patients with RAEB in transformation (RAEB-t) and three patients with chronic myelomonocytic leukaemia (CMMoL). In addition, we also studied six cases with acute myeloid leukaemia (AML) arising from MDS (AML-MDS) and ten control subjects. Fatal pancytopenia was the cause of death in 19 out of 51 patients. The apoptotic rate was higher in MDS patients (5.5%) than in control subjects (0.6%) and AML-MDS patients (0.4%). The percentage of MIB-1 positive cells was higher in MDS and AML-MDS than in control. The percentage of CD34-positive cells was higher in AML-MDS, RAEB, RAEB-t and CMMoL patients than control subjects and RA patients. Our findings indicate the activation of both the proliferative and apoptotic rates in MDS. Poor prognosis correlated significantly with higher apoptotic rates, but not with percentages of MIB-1 and CD34-positive cells. Our results suggest that apoptosis might be a useful prognostic factor and inhibition of apoptotic mechanisms may induce leukaemic transformation in MDS.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10997968     DOI: 10.1046/j.1365-2141.2000.02228.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

Review 1.  Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes.

Authors:  R Tehranchi
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

2.  Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome.

Authors:  Krishnan Allampallam; Vilasini Shetty; Suneel Mundle; Diya Dutt; Howard Kravitz; Poluru L Reddy; Sairah Alvi; Naomi Galili; Gurveen S Saberwal; Shalini Anthwal; Maliha W Shaikh; Aaron York; Azra Raza
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

3.  Expression of the proliferation-associated nuclear protein MIB-1 and its relationship with microvascular density in bone marrow biopsies of patients with myelodysplastic syndromes.

Authors:  Michael G Alexandrakis; Freda H Passam; Despina S Kyriakou; Constantina Dambaki; George Katrinakis; George Tsirakis; John Konsolas; Efstathios N Stathopoulos
Journal:  J Mol Histol       Date:  2004-11       Impact factor: 2.611

4.  Treatment of myelodysplastic syndrome with agents interfering with inhibitory cytokines.

Authors:  P Greenberg
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

5.  Gene expression patterns in myelodyplasia underline the role of apoptosis and differentiation in disease initiation and progression.

Authors:  Merav Bar; Derek Stirewalt; Era Pogosova-Agadjanyan; Vitas Wagner; Ted Gooley; Nissa Abbasi; Ravi Bhatia; H Joachim Deeg; Jerald Radich
Journal:  Transl Oncogenomics       Date:  2008-05-29

Review 6.  The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes.

Authors:  Azra Raza; Naomi Galili
Journal:  Nat Rev Cancer       Date:  2012-12       Impact factor: 60.716

Review 7.  The potential of proliferative and apoptotic parameters in clinical flow cytometry of myeloid malignancies.

Authors:  Stefan G C Mestrum; Anton H N Hopman; Frans C S Ramaekers; Math P G Leers
Journal:  Blood Adv       Date:  2021-04-13

8.  Large-scale gene network analysis reveals the significance of extracellular matrix pathway and homeobox genes in acute myeloid leukemia: an introduction to the Pigengene package and its applications.

Authors:  Amir Foroushani; Rupesh Agrahari; Roderick Docking; Linda Chang; Gerben Duns; Monika Hudoba; Aly Karsan; Habil Zare
Journal:  BMC Med Genomics       Date:  2017-03-16       Impact factor: 3.063

9.  The orphan nuclear receptor EAR-2 (NR2F6) inhibits hematopoietic cell differentiation and induces myeloid dysplasia in vivo.

Authors:  Christine V Ichim; Dzana D Dervovic; Lap Shu Alan Chan; Claire J Robertson; Alden Chesney; Marciano D Reis; Richard A Wells
Journal:  Biomark Res       Date:  2018-12-07

Review 10.  Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions.

Authors:  Ali N Chamseddine; Elias Jabbour; Hagop M Kantarjian; Zachary S Bohannan; Guillermo Garcia-Manero
Journal:  Curr Oncol Rep       Date:  2016-01       Impact factor: 5.945

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.